Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

• Status: Recruiting
• Trial end date: 2026-09-30

Summary

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

• Phase: Phase 3

Details

• Lead Sponsor: Children's Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: 3-Iodobenzylguanidine; Aldesleukin; Busulfan; Carboplatin; Cisplatin; Crizotinib; Cyclophosphamide; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide; Etoposide phosphate; Interleukin-2; Isotretinoin; Liposomal doxorubicin; Mechlorethamine; Melphalan; Nitrogen Mustard Compounds; Razoxane; Sargramostim; Succinylcholine; Thiotepa; Topotecan; Tretinoin; Vincristine; Vitamin A